Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS
NCT02061332Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2009
- Primary completion
- Aug 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of her2 peptide-pulsed dendritic cells in ductal carcinoma in situ (DCIS) (3 arms), sponsored by Abramson Cancer Center. Primary endpoints: Blood Pressure, Temperature and 1 more. Started Jul 2009; status: completed.
02
Drugs
her2 peptide-pulsed dendritic cells
03
Conditions
ductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02061332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02061332.